BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

BlossomHill Therapeutics will showcase its oncology pipeline at two September 2026 scientific and investor conferences, with webcast access for one event.

Rhea-AI Summary

BlossomHill Therapeutics (BLSM) will present at two September 2026 industry and investor conferences focused on oncology and drug development.

Chief Medical Officer Geoff Oxnard, M.D., will speak at the 8th Annual RAS-Targeted Drug Development Summit at The Colonnade Hotel in Boston on Thursday, September 10, at 10:00 a.m. PT / 1:00 p.m. ET. Founder, President and CEO J. Jean Cui, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on Tuesday, September 15, at 7:30 a.m. PT / 10:30 a.m. ET, with webcast access and a 90-day replay available via the company’s Investor Relations website.

Market Reaction – BLSM

+3.76% $20.11

15m delay

+3.76% Vs previous close

$20.11 Last Price

$19.38 $20.63 Day Range

$584.80M Market Cap

0.7x Rel. Volume

Following this news, BLSM has gained 3.76%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $20.11.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

Recent insider records show 1,562,500 shares bought and none sold, adding an ownership datapoint alo...

Analysis

Recent insider records show 1,562,500 shares bought and none sold, adding an ownership datapoint alongside this scheduling notice. That comparison does not resolve clinical execution or future capital requirements.

Key Figures

RAS summit edition: 8th Annual Wainwright conference edition: 28th Annual RAS summit date: September 10 +4 more

7 metrics

RAS summit edition 8th Annual RAS-Targeted Drug Development Summit

Wainwright conference edition 28th Annual H.C. Wainwright Global Investment Conference

RAS summit date September 10 Scheduled presentation

Wainwright conference date September 15 Scheduled presentation

Archived replay 90 days H.C. Wainwright webcast

FDA-approved drugs three FDA-approved drugs Management track record

Prior treatment generation 3rd generation EGFR TKI C797S resistance population

Historical Context

2 past events · Latest: Sep 01 (Positive)

Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Clinical data presentation	Positive	+3.8%	Updated Phase 1/2 SOLARA data presentation was followed by a 3.77% move.
Aug 18	FDA Fast Track designation	Positive	-1.7%	FDA Fast Track designation announcement was followed by a -1.71% move.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions were mixed: clinical-data presentation news coincided with 3.77%, while Fast Track news coincided with -1.71%.

Key Terms

fast track designation, non-covalent, macrocyclic, pan-kras switch ii inhibitor

4 terms

fast track designation regulatory

"which has received Fast Track designation for the C797S resistance population"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

non-covalent medical

"an investigational, non-covalent, macrocyclic, brain active"

Non-covalent describes a type of interaction where molecules stick together through weak, reversible forces rather than forming permanent chemical bonds. For investors, non-covalent binding in drugs or diagnostics signals treatments that are often adjustable, shorter-acting, and potentially easier to reverse or fine-tune than covalent counterparts, which affects safety profiles, dosing strategies, patenting approaches and how a product may perform in the market.

macrocyclic medical

"an investigational, non-covalent, macrocyclic, brain active"

A macrocyclic is a large, ring-shaped molecule used in drugs and other products; imagine a tiny chemical bracelet where the ends are joined to form a loop. Its ring structure often gives unusual stability, the ability to bind targets precisely, and distinct behavior in the body compared with smaller molecules. For investors, macrocyclics can signal potential for novel therapies, stronger patent protection, and often higher development or manufacturing complexity and cost.

pan-kras switch ii inhibitor medical

"a preclinical, non-covalent, selective, pan-KRAS Switch II inhibitor"

A pan-KRAS switch II inhibitor is a type of experimental cancer drug designed to bind a specific pocket (the “switch II” region) on multiple mutant forms of the KRAS protein, which drives growth in many tumors. By blocking KRAS’s activity across several mutation variants rather than just one, these drugs aim to treat a broader set of cancers; for investors, that means potentially larger patient populations and different development risks compared with mutation-specific therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference.

Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill will present at the RAS-Targeted Drug Development Summit, and Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill will present at the H.C. Wainwright conference. Dr. Cui and other members of the management team will be available for one-on-one meetings.

Conference: 8th Annual RAS-Targeted Drug Development Summit
Location: The Colonnade Hotel, Boston
Date: Thursday, September 10
Time: 10:00 am Pacific Time | 1:00 pm Eastern Time

Conference:  H.C. Wainwright 28th Annual Global Investment Conference
Location:  Lotte New York Palace Hotel, Holmes Room II, 4^th Floor, New York City
Date: Tuesday, September 15
Time: 7:30 am Pacific Time | 10:30 am Eastern Time

Webcast access for the H.C. Wainwright conference will be available on the Investor Relations section of the company’s website. An archived replay will be available for 90 days.

About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR^TM inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). The company’s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch II inhibitor for potential future development in diverse KRAS-mutant tumors. BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit bhtherapeutics.com and follow us on LinkedIn and X.

Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com

Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com

FAQ

What conferences will BlossomHill Therapeutics (BLSM) present at in September 2026?

BlossomHill Therapeutics will present at the 8th Annual RAS-Targeted Drug Development Summit in Boston and the H.C. Wainwright 28th Annual Global Investment Conference in New York City, both taking place in September 2026.

When and where is BlossomHill Therapeutics presenting at the 8th Annual RAS-Targeted Drug Development Summit?

BlossomHill’s Chief Medical Officer, Geoff Oxnard, M.D., will present at the 8th Annual RAS-Targeted Drug Development Summit at The Colonnade Hotel in Boston on Thursday, September 10, at 10:00 a.m. Pacific / 1:00 p.m. Eastern.

When is BlossomHill Therapeutics’ presentation at the H.C. Wainwright 28th Annual Global Investment Conference and who will speak?

Founder, President and CEO J. Jean Cui, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, at 7:30 a.m. Pacific / 10:30 a.m. Eastern at the Lotte New York Palace Hotel in New York City.

How can investors access the BlossomHill Therapeutics (BLSM) presentation at the H.C. Wainwright conference?

Webcast access for the H.C. Wainwright 28th Annual Global Investment Conference presentation will be available via the Investor Relations section of BlossomHill Therapeutics’ website, with an archived replay accessible for 90 days.

What are the key clinical programs BlossomHill Therapeutics (BLSM) is highlighting?

The company’s lead program is BH-30643, a mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC with Fast Track designation for the C797S resistance population. BlossomHill is also developing BH-30236 for relapsed or refractory AML and higher-risk MDS, and BH-501284, a preclinical pan-KRAS Switch II inhibitor.